183 Diagnostic utility of molecular and imaging biomarkers 2 Table 39. Hypothetical worst-case scenario estimated pooled test performance of Afirma® GEC in indeterminate thyroid nodules reference ni TP FP FN TN sensitivity (95% CI), % specificity (95% CI), % LR+ (95% C+I) LR- (95% CI) Alexander 2012 210 46 77 5 82 90 (79-97) 52 (44-60) 1.86 (1.55-2.24) 0.19 (0.08-0.44) Alexander 2014 326 47 92 160 10 23 (17-29) 10 (5-17) 0.25 (0.19-0.33) 7.88 (4.36-14.27) Harrell 2014 58 17 19 17 3 50 (32-68) 14 (3-35) 0.58 (0.40-0.84) 3.67 (1.22-11.06) Lastra 2014 132 22 40 68 2 24 (16-35) 5 (1-16) 0.26 (0.18-0.37) 15.87 (4.08-61.67) McIver 2014 72 5 39 13 3 28 (10-53) 7 (1-19) 0.30 (0.14-0.63) 10.11 (3.27-31.22) Sullivan 2014 14 2 5 5 1 29 (4-71) 17 (0-64) 0.34 (0.10-1.17) 4.29 (0.67-27.24) Brauner 2015 72 6 39 23 3 21 (8-40) 7 (1-19) 0.22 (0.11-0.46) 11.10 (3.67-33.56) Celik 2015 40 10 13 9 2 53 (29-76) 13 (2-40) 0.61 (0.38-0.97) 3.55 (0.90-14.04) Marti 2015 165 27 77 54 7 33 (23-45) 8 (3-16) 0.36 (0.27-0.50) 8.00 (3.87-16.53) Noureldine 2015 222 72 125 8 10 90 (81-96) 7 (4-13) 0.97 (0.89-1.06) 1.35 (0.56-3.28) Witt 2016 32 6 9 14 0 30 (12-54) 0 (0-34) 0.33 (0.17-0.63) 13.81 (0.91-208.95) Wu 2016 214 50 57 78 12 39 (31-48) 17 (9-28) 0.47 (0.37-0.60) 3.50 (2.06-5.97) Yang 2016 189 32 62 75 5 30 (21-40) 7 (2-17) 0.32 (0.24-0.44) 9.39 (4.01-22.02) POOLED RESULTS 1,746 342 654 529 140 42.5 (27.9-58.4) 10.4 (6.3-16.6) 0.47 (0.32-0.71) 5.54 (2.86-10.76) FN: false negative. FP: false positive. LR+: positive likelihood ratio. LR-: negative likelihood ratio. ni : number of included indeterminate nodules. TN: true negative. TP: true positive.
RkJQdWJsaXNoZXIy MTk4NDMw